Pipeline
PipelineRecombinant streptokinase. Recombinant streptokinase is a clot dissolving –i.e. fibrinolytic, agent. The mechanism of action implies the activation of plasminogen to produce plasmin, which acts in turn to break down and dissolve unwanted blood clots that can be life threatening. Recombinant streptokinase is indicated for the treatment of certain cases of myocardial infarction, as well as in cases of pulmonary embolism.
Agalsidase beta (alpha galactosidase) and imiglucerase. Agalsidase beta (alpha galactosidase) and imiglucerase are enzymes used to treat congenital deficiencies of lysosomal enzymes involved in metabolism. Patients suffering this condition are unable to metabolize and breakdown certain types of fats, which may be toxic (sphingolipids), resulting in a buildup of fatty material in the spleen, liver, kidneys, lungs, brain and bone marrow. Deficiencies of the endogenous lysosomal enzyme alpha-galactosidase A or alpha-GAL lead to Fabry’s disease, an inherited disorder. Agalsidase beta is a human recombinant enzyme used to treat patients suffering from Fabry’s disease.
Likewise, deficiencies of the endogenous lysosomal enzyme glucocerebrosidase lead to Gaucher’s disease. Imiglucerase is the recombinant human version of beta glucocerebrosidase used to treat patients suffering from Gaucher’s disease.
Rituximab and etanercept. Rituximab is a monoclonal antibody used to treat non-Hodgkin’s lymphoma and also in the treatment of certain immunological disorders and to prevent organ transplant rejection. Etanercept is a tumoral necrosis factor inhibitor. It is used to treat several autoimmune diseases, mainly rheumatoid arthritis.
Bio Sidus retuximab and etanercept product candidates are being developed for expression in the milk of cloned transgenic cows.
